Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30251% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Champions Oncology's enterprise value was $62.74M on Nov 11, 2026, against $79.88M a year earlier. Over the last 5 years it ranged from $42.86M to $147.80M, with a median of $77.25M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $62.74M | -28.3% |
| 2025 | Dec 31, 2025 | $87.50M | -23.7% |
| 2024 | Dec 31, 2024 | $114.65M | +61.7% |
| 2023 | Dec 29, 2023 | $70.88M | +40.9% |
| 2022 | Dec 30, 2022 | $50.32M | -53.4% |
| 2021 | Dec 31, 2021 | $108.05M | -20.4% |
| 2020 | Dec 31, 2020 | $135.69M | +44.3% |
| 2019 | Dec 31, 2019 | $94.01M | +7.2% |
| 2018 | Dec 31, 2018 | $87.66M | +108.8% |
| 2017 | Dec 29, 2017 | $41.97M | +79.2% |
| 2016 | Dec 30, 2016 | $23.42M | -13.0% |
| 2015 | Dec 31, 2015 | $26.91M | -18.1% |
| 2014 | Dec 31, 2014 | $32.87M | -6.9% |
| 2013 | Dec 31, 2013 | $35.31M | +331.1% |
| 2012 | Dec 31, 2012 | $8.19M | -56.3% |
| 2011 | Dec 30, 2011 | $18.73M | – |
See a number that looks wrong?